FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED (FPH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

FPH - FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

Fisher & Paykel Healthcare is a designer and manufacturer of systems used in respiratory care and treatment of sleep disorders. It was separated from Fisher & Paykel and listed on the ASX and NZX in 2001. A brief Nasdaq listing was terminated in 2003. Only 1% of its revenues stems from New Zealand.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$18.78

17 May
2022

-0.300

OPEN

$18.97

-1.57%

HIGH

$18.97

392,123

LOW

$18.57

TARGET
$27.00 43.8% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
FPH: 1
Title FY22
Forecast		 FY23
Forecast
EPS (cps) 71.1 xxx
DPS (cps) 36.4 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 26.8 xxx
Dividend Yield 1.9% xxx
Div Pay Ratio(%) 51.2% xxx
This company reports in NZD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 2.23%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.80

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 02/12 - ex-div 16.28c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx85.3
DPS All xxxxxxxxxxxxxxx41.7
Sales/Revenue xxxxxxxxxxxxxxx1,819.2 M
Book Value Per Share xxxxxxxxxxxxxxx242.7
Net Operating Cash Flow xxxxxxxxxxxxxxx583.9 M
Net Profit Margin xxxxxxxxxxxxxxx26.91 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx41.81 %
Return on Invested Capital xxxxxxxxxxxxxxx39.65 %
Return on Assets xxxxxxxxxxxxxxx29.68 %
Return on Equity xxxxxxxxxxxxxxx41.81 %
Return on Total Capital xxxxxxxxxxxxxxx49.85 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx265.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

24/03/2022

3

Neutral

$27.00

43.77%

Credit Suisse downgraded expectations for Fisher & Paykel Healthcare's hospital revenue by -12% and -14% in FY23 and FY24 respectively, reiterating difficulty in a clear read on the market. 

The broker noted usage of the company's nasal high flow therapy has declined from a peak as covid hospitalisations decrease and usage remains constrained outside of covid. 

Adjusting for company guidance, Credit Suisse deceases its FY22 net profit forecast -8% to NZ$366m, representing a -30% year-on-year decline.

The Neutral rating is retained and the target price decreases to $27.00 from $34.00.

FORECAST
Credit Suisse forecasts a full year FY22 dividend of 30.10 cents and EPS of 59.26 cents.
Credit Suisse forecasts a full year FY23 dividend of 31.04 cents and EPS of 47.97 cents.

UBS

xx/xx/xxxx

5

xxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

FPH STOCK CHART

FNArena News on FPH

1
April In Review: ASX Defensives Shine

May 04 2022 - Australia
2
March In Review: War Puts ASX On Pedestal

Apr 06 2022 - Australia
3
Australian Broker Call *Extra* Edition – Mar 29, 2022

Mar 29 2022 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 28, 2022

Mar 28 2022 - Daily Market Reports
5
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia